The Triglyceride/Glucose Index and SGLT-2 Inhibitors

Investigation of the Triglyceride/Glucose Index in Diabetic Patients Using SGLT-2 Inhibitor

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05915884

Enrollment

Registered

2023-06-23

Start date

2023-06-10

Completion date

2024-01-28

Last updated

2024-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Disease, Diabetes

Keywords

SGLT-2 inhibitor, triglyceride index

Brief summary

This study was designed to evaluate the change in triglyceride glucose index, one of the atherosclerotic markers, in patients with type 2 DM followed in the Internal Medicine Clinic of Samsun University, Samsun Training, and Research Hospital. Methods: The data of the patients who were followed up for at least 3 months by making a retrospective file review will be recorded and analyzed. It is planned to start the study following the ethics committee's approval.

Detailed description

The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria stated below, the patients will be evaluated and the data of the patients admitted to the study will be analyzed. The triglyceride glucose index of the patients before starting the SGLT-2 injection and the trig/glucose index at the end of 3 months of treatment will be calculated by the researchers using the data in the system. No additional blood tests or laboratory analyses will be performed on the patients. Triglyceride, glucose, and glycosylated hemoglobin values were checked at the beginning of the treatment and at the 3rd-month follow-up.

Interventions

OTHERSGLT-2 inhibitors

This study is an observational study. It is not planned to do an interventional activity.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Type 2 DM * Age \>18 years old * Dapagliflozin 10 mg or empagliflozin 10 mg or 25 mg * 3 months follow-up period

Exclusion criteria

* Type 1 diabetes * Gestational diabetes * Age \< 18 years old * Insufficient or missed laboratory test results * Medical treatment for dyslipidemia * Hypothyroidism

Design outcomes

Primary

Measure	Time frame	Description
Change in triglyceride index	3 months	Decreased triglyceride index among patients using SGLT-2 inhibitors.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026